Communiqués Alaunos Therapeutics, Inc.

Actions

TCRT

US98973P3091

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/06/2026			Varia. 5j.	Varia. 1 janv.
2,370 ^USD	+13,94%		+9,72%	-26,63%

29/06	Alaunos Therapeutics publie de nouvelles données précliniques sur l'ALN1003 montrant une réduction du poids du foie après ajustement du taux de graisse corporelle dans une étude de 48 jours sur des souris DIO	CI
26/05	Alaunos Therapeutics fait état d'une amélioration métabolique globale avec l'ALN1003 dans des études sur des souris obèses	CI

Communiqués

29/06	Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study	AQ
26/05	Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	AQ
18/05	Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models	AQ
15/05	Ziopharm: Q1 Earnings Snapshot	AQ
01/04	Ziopharm: Q4 Earnings Snapshot	AQ
02/03	Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders	AQ
14/11	Ziopharm: Q3 Earnings Snapshot	AQ
15/08/25	Ziopharm: Q2 Earnings Snapshot	AQ
23/06/25	Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering	AQ
15/05/25	Ziopharm: Q1 Earnings Snapshot	AQ
14/11/24	Ziopharm: Q3 Earnings Snapshot	AQ
15/08/24	Ziopharm: Q2 Earnings Snapshot	AQ
15/05/24	Ziopharm: Q1 Earnings Snapshot	AQ
14/11/23	Ziopharm: Q3 Earnings Snapshot	AQ
14/11/23	Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives	AQ
14/08/23	Ziopharm: Q2 Earnings Snapshot	AQ
14/08/23	Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives	AQ
29/06/23	Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies	AQ
12/06/23	ALAUNOS THERAPEUTICS, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
25/05/23	Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting	AQ
10/05/23	Ziopharm: Q1 Earnings Snapshot	AQ
10/05/23	Alaunos Therapeutics Reports First Quarter 2023 Financial Results	AQ
03/05/23	Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023	AQ
26/04/23	Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting	AQ
03/04/23	ALAUNOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8-K)	AQ